Is palliative care valued the same as hospice in M&A?

No. While many agencies offer both, palliative care is valued differently. Palliative care typically operates under a fee-for-service or value-based contract model with non-terminal patients, generating different revenue economics than the Medicare Hospice Benefit per-diem model. Standalone palliative care platforms generally trade at slightly lower multiples than hospice, but combined hospice + palliative platforms often command premiums for continuum-of-care positioning.

What are typical EBITDA multiples for palliative care agencies in 2026?

Standalone community-based palliative care platforms with $3M+ EBITDA trade at 8x–11x. Smaller platforms with $1M–$3M EBITDA typically clear 6x–9x. Hospice + palliative care combined platforms trade at hospice multiples (10x–13x+) with palliative care contributing as a growth and continuum-of-care driver.

Who buys palliative care companies?

The most active buyers are hospice strategics adding palliative care to create continuum platforms (Compassus, Pennant, Bristol Hospice, Empath Health, Care Synergy), PE-backed hospice platforms in build mode, large home health and home care platforms expanding into higher-acuity services, and value-based care organizations (ACOs, Medicare Advantage plans, MSSP entities) acquiring palliative capability.

How does value-based contracting affect palliative care valuation?

Value-based contracts (with Medicare Advantage plans, ACOs, and MSSP entities) are increasingly the central economic structure for palliative care platforms. Buyers pay premium multiples for agencies with multiple value-based contracts, demonstrated cost-savings outcomes, and PMPM (per-member-per-month) revenue durability. Fee-for-service-only palliative care is valued more conservatively.

What due diligence is unique to palliative care M&A?

Palliative diligence focuses on payer contract economics (FFS, PMPM, shared savings), clinical outcomes documentation, hospice referral conversion patterns (where applicable), clinician licensure and turnover (palliative-trained physicians, NPs, RNs are scarce), and the integrity of advance care planning and goals-of-care documentation.

Palliative Care M&A 2026: Valuation Guide

Palliative care has rapidly emerged as a distinct M&A category over the past five years. While hospice continues to dominate end-of-life care headlines and valuations, community-based palliative care — serving patients with serious illness who are not yet hospice-eligible or have not elected hospice — is increasingly its own service line, with its own buyers, contract structures, and valuation dynamics.

For owners of palliative care platforms, or hospice operators with material palliative care lines, understanding the distinction is essential to maximizing exit value.

Palliative Care Is Not Hospice (For M&A Purposes)

The clinical and operational overlap between hospice and palliative care is real. The financial and valuation distinction is also real.

Dimension	Hospice	Palliative Care
Patient eligibility	Terminal (≤6 month prognosis), elects hospice benefit	Serious illness; non-terminal or pre-election
Primary payer	Medicare Hospice Benefit (per-diem)	Fee-for-service, value-based contracts (PMPM, shared savings)
Revenue model	Per-diem MHB	FFS visits + value-based contracts
Clinical model	Interdisciplinary IDG, focused on comfort	Symptom management, goals-of-care, can include disease-modifying treatment
Length of episode	Often weeks to months	Can be months to years
Typical buyer	Hospice strategics, PE hospice platforms	Hospice + value-based care organizations, ACOs, MA plans
Valuation multiple	9x–14x+	6x–11x standalone; combined hospice + palliative often hospice-multiple range

For combined hospice + palliative platforms, the valuation typically clears at the hospice multiple range with palliative care contributing as a strategic growth driver — particularly for buyers focused on continuum-of-care positioning and value-based contracting capability.

Why Palliative Care M&A Is Active in 2026

1. Aging population with rising serious illness prevalence. Demand for palliative care services is growing faster than supply.

2. Value-based care convergence. Medicare Advantage plans, ACOs, and MSSP entities increasingly contract for palliative care as a cost-savings and quality-of-care intervention. This payer demand creates durable PMPM revenue.

3. Hospice strategics building continuums. National hospice strategics (Compassus, Pennant, Bristol Hospice, Empath, Care Synergy) increasingly want palliative care capability to capture upstream patient relationships.

4. PE platform build. PE-backed hospice and home-based care platforms are adding palliative care to drive multiple expansion at exit.

5. Mid-market fragmentation. The community-based palliative care market remains fragmented; buyer-to-target ratio is favorable for sellers.

Sub-Sector Valuation Ranges (Q2 2026)

Asset Type	EBITDA Size	Typical Multiple Range
Standalone community palliative care	sub-$1M	5x–7x
Standalone community palliative care	$1M–$3M	6x–9x
Standalone community palliative care	$3M+	8x–11x
Standalone with strong VBC contracts	$3M+	9x–12x
Combined hospice + palliative	$5M+	10x–13x+ (hospice-range)
Multi-state palliative platform	$5M+	9x–12x

Premiums apply for: multiple value-based contracts, demonstrated cost-savings outcomes, palliative-trained physician and NP staffing, geographic density, and integrated hospice operation.

Payer and Contract Dynamics

Palliative care economics in 2026 are increasingly defined by the contract portfolio.

Fee-for-Service (FFS)

Medicare Part B (E/M codes, advance care planning codes, chronic care management codes)
Commercial insurance FFS where contracted
Reasonable margin economics; less attractive to PE than VBC

PMPM Value-Based Contracts

Medicare Advantage plans contracting for palliative member services
ACOs (MSSP, Medicare ACO REACH)
Direct contracts with health systems
Premium valuation driver — durable, predictable revenue

Shared Savings / Risk-Bearing Contracts

Upside-only or two-sided risk arrangements
Outcomes documentation and actuarial credibility required
Highest-multiple contract type when well-executed

Per-Diem Palliative Care (Hospital or SNF Contracts)

Inpatient palliative consult services
Lower-margin but stable
Important for some integrated platforms

Hospice Conversion Pipeline

Palliative care patients who later elect hospice are a meaningful value driver for combined platforms
Buyer underwriting increasingly weighted to documented conversion rates

Service Line Considerations

Community-Based Palliative Care (CBPC)

Home-based palliative visits by interdisciplinary team
Most common standalone model
Operating economics depend heavily on contract mix

Outpatient / Clinic-Based Palliative Care

Office or telehealth palliative consultation
Lower fixed cost; easier scaling
Often integrated with hospital systems

Inpatient Palliative Consultation Services

Hospital-based palliative consult under contract
Per-consultation or block-payment economics
Important integration play for some buyers

Pediatric Palliative Care

Highly specialized
Limited buyer pool but premium valuations for quality programs
Often state Medicaid waiver-funded

The Most Active Palliative Care Buyers in 2026

Strategic Hospice Buyers Adding Palliative

Compassus — Continuum strategy, active palliative acquisition
Pennant Group (NASDAQ: PNTG) — Hospice and home health, building palliative
Bristol Hospice — National hospice with palliative additions
Empath Health — Florida-based, integrated continuum
Care Synergy / Cooperative network
VITAS Healthcare (Chemed subsidiary) — Selective palliative integration
AccentCare — Multi-service home-based care

Value-Based Care Acquirers

Medicare Advantage plans acquiring palliative capability
ACO REACH entities and MSSP organizations building serious-illness platforms
Aledade and similar primary-care platforms
Health systems building post-acute and serious-illness continuum

PE-Backed Platforms

Multiple PE-backed hospice platforms (Webster, Blue Wolf, Audax-backed) adding palliative
Standalone palliative-focused PE platforms (limited but emerging)
Independent sponsors targeting smaller community palliative platforms

Diligence Items Unique to Palliative M&A

Buyer diligence in palliative care focuses on:

Contract Portfolio

VBC contract review (PMPM rates, performance terms, renewal mechanics)
FFS contract review by payer
Hospice referral pipeline documentation (for combined platforms)
Health system contract review

Clinical and Outcomes

Palliative-trained physician (HPM-boarded), NP, RN staffing
Outcomes documentation (symptom management, hospitalization avoidance, ED avoidance)
Advance care planning completion rates
Goals-of-care documentation integrity
Quality measures (CAHPS Hospice if combined; quality programs as applicable)

Workforce

Palliative-trained clinician scarcity is a structural challenge
Retention and recruitment pipeline
Physician compensation models
NP and RN turnover

Compliance

Medicare Part B billing compliance
Advance care planning code use
E/M coding accuracy
HIPAA and documentation compliance

Operational Integration

For combined hospice + palliative: documentation of patient conversion rates and clinical pathway integrity
For VBC contracts: actuarial documentation and outcomes attribution

Common Palliative Seller Mistakes

1. Selling palliative as hospice. Buyers will discover the distinction immediately. Position palliative correctly in the CIM with payer-specific economics.

2. Underweighting VBC contract documentation. PMPM contracts are the central value driver; document rigorously.

3. Ignoring clinician scarcity in projections. Growth projections that assume readily available palliative-trained clinicians are not credible.

4. Single-buyer outreach. The buyer pool — strategic hospices, VBC organizations, PE platforms — is broader than most owners realize.

5. Disorganized hospice conversion data. For combined platforms, hospice conversion economics are a meaningful value driver. Document carefully.

Preparing a Palliative Care Platform for Sale

The 12–24 months before sale are when palliative platforms most successfully build value.

Operationally:

Pursue and renew value-based contracts
Build outcomes measurement and documentation
Reduce clinician turnover; document retention strategy
Build hospice referral and conversion documentation (for combined platforms)
Diversify payer and contract mix

Financially:

Sell-side Quality of Earnings
Contract-level economic analysis
VBC contract attribution and outcomes documentation

Legally:

Healthcare regulatory compliance audit
VBC contract assignment review
HIPAA and documentation compliance

How Hendon Partners Helps Palliative Care Sellers

Hendon Partners advises owners of community-based palliative care platforms and hospice-palliative continuum platforms through preparation, sale process, and close. Our buyer network includes the hospice strategics, VBC organizations, and PE platforms most active in palliative care M&A in 2026.

Schedule a confidential palliative-focused conversation with Hendon Partners →

Hendon Partners is a sell-side only M&A advisory firm with deep expertise in hospice and palliative care transactions across the United States.

Palliative Care Agency Valuation & M&A in 2026: Distinguished from Hospice, Different Multiples